BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 4, 2008
View Archived Issues
Pim-2 kinase inhibitors identified as potential drugs for the treatment of inflammation
Read More
CB2 ligands developed at Abbott undergoing optimization
Read More
Urotensin-II receptor antagonist optimization leads to JNJ-39327041
Read More
Characterization of Pfizer's novel CP-690550 in de novo kidney transplant patients
Read More
Novel antiviral agents claimed by Novartis
Read More
Oncothyreon presents update on clinical development activities
Read More
Chelsea Therapeutics initiates patient dosing in Study 301 phase III trial of droxidopa in NOH
Read More
Neurocrine presents elagolix PETAL study results in endometriosis
Read More
FDA approves Sandoz's Omnitrope Pen 10 with liquid cartridge for growth hormone deficiency
Read More
PHA-848125, a novel CDK inhibitor orally active in preclinical model of ovarian carcinoma
Read More
Ikaria acquires North American rights to Lucassin for HRS from Orphan Therapeutics
Read More
Refinement of H3 receptor antagonists for wakefulness continues at Arena Pharmaceuticals
Read More
Wyeth advances synthesis of dual selective serotonin reuptake inhibitors/5-HT1A antagonists
Read More
Diffusion initiates phase I/II trans-sodium crocetinate trial in patients with PAD
Read More
Recent patents cover novel anticancer agents
Read More
OSI initiates clinical development program for antidiabetes candidate, PSN-821
Read More
Plexxikon commences phase I trial for novel kinase inhibitor, PLX-5568
Read More
New immunmodulatory agents disclosed by Otsuka Chemical
Read More
Sangamo BioSciences initiates phase II trial for SB-509 in ALS
Read More
Agile achieves phase II study endpoints with low-dose contraceptive patch
Read More
Phase II study shows Arcalyst reduces gout flares by 81%
Read More
OncoGenex grants Eagle Pharmaceuticals exclusive worldwide rights to Tocosol paclitaxel
Read More
Anavex successfully completes preclinical studies of ANAVEX 2-73 in Alzheimer's disease
Read More
Dako acquires InstrumeC
Read More
ZymoGenetics and Merck Serono restructure 2001 partnership agreement
Read More